PMID- 37179289
OWN - NLM
STAT- MEDLINE
DCOM- 20230515
LR  - 20230516
IS  - 1472-6874 (Electronic)
IS  - 1472-6874 (Linking)
VI  - 23
IP  - 1
DP  - 2023 May 13
TI  - Urinary phytoestrogens and the risk of uterine leiomyomata in US women.
PG  - 261
LID - 10.1186/s12905-023-02381-5 [doi]
LID - 261
AB  - BACKGROUND: Uterine leiomyomata (UL) is a common gynecological disease in women. 
      Studied on the relationship between single metabolites of urinary phytoestrogens 
      and UL, especially for the combined effects of mixed metabolites on UL still are 
      insufficient. METHODS: In this cross-sectional study, we included 1,579 
      participants from the National Health and Nutrition Examination Survey. Urinary 
      phytoestrogens were assessed by measuring urinary excretion of daidzein, 
      genistein, equol, O-desmethylangolensin, enterodiol and enterolactone. The 
      outcome was defined as UL. Weighted logistic regression was used to analyze the 
      association between single metabolites of urinary phytoestrogens and UL. Notably, 
      we adopted the weighted quantile sum (WQS) regression, Bayesian kernel machine 
      regression (BKMR), and quantile g-computation (qgcomp) models, to investigate the 
      combined effects of six mixed metabolites on UL. RESULTS: The prevalence of UL 
      was approximately 12.92%. After adjusting age, race/ethnicity, marital status, 
      drinking status, body mass index, waist circumference, menopausal status, ovary 
      removed status, use of female hormones, hormones/hormone modifiers, total energy, 
      daidzein, genistein, O-desmethylangolensin, enterodiol, and enterolactone, the 
      association of equol with UL was significant [Odds ratio (OR) = 1.92, 95% 
      confidence interval (CI): 1.09-3.38]. In the WQS model, mixed metabolites of 
      urinary phytoestrogen had a positive association with UL (OR = 1.68, 95%CI: 
      1.12-2.51), with the highest weighted chemical of equol. In the gpcomp model, 
      equol had the largest positive weight, followed by genistein and enterodiol. In 
      the BKMR model, equol and enterodiol have positive correlation on UL risk, while 
      enterolactone has negative correlation. CONCLUSION: Our results implied a 
      positive association between the mixed metabolites of urinary phytoestrogen and 
      UL. This study provides evidence that urinary phytoestrogen-metabolite mixture 
      was closely related to the risk of female UL.
CI  - (c) 2023. The Author(s).
FAU - Yang, Fang
AU  - Yang F
AD  - Department of Obstetrics and Gynecology, The First Affiliated Hospital of Soochow 
      University, No.899 Pinghai Road, Suzhou, 215006, P. R. China.
FAU - Chen, Youguo
AU  - Chen Y
AD  - Department of Obstetrics and Gynecology, The First Affiliated Hospital of Soochow 
      University, No.899 Pinghai Road, Suzhou, 215006, P. R. China. ygchensu@163.com.
LA  - eng
PT  - Journal Article
DEP - 20230513
PL  - England
TA  - BMC Womens Health
JT  - BMC women's health
JID - 101088690
RN  - 0 (Phytoestrogens)
RN  - X01E7E1D6H (2,3-bis(3'-hydroxybenzyl)butyrolactone)
RN  - 76543-16-3 (2,3-bis(3'-hydroxybenzyl)butane-1,4-diol)
RN  - DH2M523P0H (Genistein)
RN  - 531-95-3 (Equol)
SB  - IM
MH  - Humans
MH  - Female
MH  - *Phytoestrogens/urine
MH  - Genistein
MH  - Equol
MH  - Cross-Sectional Studies
MH  - Nutrition Surveys
MH  - Bayes Theorem
MH  - *Leiomyoma/epidemiology
PMC - PMC10182647
OTO - NOTNLM
OT  - NHANES
OT  - Relationship
OT  - Urinary phytoestrogens
OT  - Uterine leiomyomata
OT  - Weighted quantile sum
COIS- The authors declare no competing interests.
EDAT- 2023/05/14 01:07
MHDA- 2023/05/15 06:42
PMCR- 2023/05/13
CRDT- 2023/05/13 23:12
PHST- 2023/01/17 00:00 [received]
PHST- 2023/04/20 00:00 [accepted]
PHST- 2023/05/15 06:42 [medline]
PHST- 2023/05/14 01:07 [pubmed]
PHST- 2023/05/13 23:12 [entrez]
PHST- 2023/05/13 00:00 [pmc-release]
AID - 10.1186/s12905-023-02381-5 [pii]
AID - 2381 [pii]
AID - 10.1186/s12905-023-02381-5 [doi]
PST - epublish
SO  - BMC Womens Health. 2023 May 13;23(1):261. doi: 10.1186/s12905-023-02381-5.